The Ingress-health team recently published the very first discrete-choice based preference analysis in patients with age-related wet macula degeneration. This
In our recently published work, we have utilized data from two large retrospective datasets: a German claims dataset and the
Insights from a real-world setting, 456,586 T2DM German patients.
In our recently published work we investigated urinary tract infection (UTI)
The ISPOR 18th Annual European Congress that will be held in Milan this year, 7-11 November 2015, is almost there.
The 51st (EASD) Annual Meeting is taking place at Stockholm, Sweden, 14-18 September 2015. Prof. Thomas Wilke will be giving
Ingress-health welcomes Ilse as latest member of the team. Ilse will support health economic and outcomes research projects as junior
Between January and October 2014, 647 patients with non-valvular AF were included by 57 practitioners and 486 AF patients could
Several authors have highlighted the importance of a good response to chemotherapy in multiple myeloma (MM), especially in first line.
The ongoing introduction of novel therapies for MM provides clinicians and patients various treatment options in numerous lines of treatment.
Real world evidence (RWE) is increasingly important in guiding reimbursement, but also treatment decisions, as HTAs, health insurers and clinicians